Literature DB >> 19375398

Individual patient data meta-analysis of trials of self-monitoring of blood glucose in non-insulin treated type 2 diabetes: protocol for a systematic review.

A J Farmer1, C Heneghan, A H Barnett, M B Davidson, B Guerci, M O'Kane, U Schwedes, R Perera.   

Abstract

BACKGROUND AND AIM OF THE STUDY: Recent trials have provided differing estimates of the benefits of self-monitoring of blood glucose (SMBG) for non-insulin treated patients with type 2 diabetes. Designing and conducting randomised trials to demonstrate the efficacy of complex interventions is challenging. Variations in the components of the intervention delivered, target population selected, and reporting methods used have limited the conclusions drawn in recent systematic reviews. We will systematically examine these factors within the trials of SMBG to enable further investigation of the data through an individual patient data analysis (IPD). METHODS/
DESIGN: The IPD analysis will include data from randomised trials comparing blood glucose self-monitoring and decisions about self-management versus a control group with standardised or routine care. The data requested for each trial will include outcomes (HbA1c, blood glucose and quality of life), potential moderators of effect (e.g. demographic variables, clinical data and psychosocial factors) and intervention descriptors. The primary outcome of interest will be HbA1c. Secondary outcomes include alternative measures of glycaemia, cardiovascular risk factors, persistence with monitoring, and measures of health status, quality of life and psychosocial factors. Analysis of patient sub-groups defined by age at randomisation, gender, prior use of monitoring and health status will be carried out. An intention to treat analysis will be performed and assessed for clinical and statistical heterogeneity. DISCUSSION: With current uncertainty about the extent of benefit from SMBG for non-insulin treated patients with type 2 diabetes, this study will provide the best estimates to date of overall effectiveness, effectiveness within potential target populations, and optimal components of the intervention.

Entities:  

Mesh:

Year:  2009        PMID: 19375398     DOI: 10.1016/j.pcd.2009.03.002

Source DB:  PubMed          Journal:  Prim Care Diabetes        ISSN: 1878-0210            Impact factor:   2.459


  7 in total

1.  4th Annual Symposium on Self Monitoring of Blood Glucose (SMBG) Applications and Beyond, May 12-14, 2011, Budapest, Hungary.

Authors:  Boris N Mankovsky
Journal:  Diabetes Technol Ther       Date:  2011-10-04       Impact factor: 6.118

2.  Patient autonomy and choice in healthcare: self-testing devices as a case in point.

Authors:  Anna-Marie Greaney; Dónal P O'Mathúna; P Anne Scott
Journal:  Med Health Care Philos       Date:  2012-11

3.  Self-monitoring of blood glucose in noninsulin-treated type 2 diabetes: an overview.

Authors:  Nanne Kleefstra; Johanna Hortensius; Kornelis Jj van Hateren; Susan Jj Logtenberg; Sebastiaan T Houweling; Rijk Ob Gans; Henk Jg Bilo
Journal:  Diabetes Metab Syndr Obes       Date:  2009-09-09       Impact factor: 3.168

Review 4.  The role of self-monitoring of blood glucose in patients treated with SGLT-2 inhibitors: a European expert recommendation.

Authors:  Oliver Schnell; Hasan Alawi; Tadej Battelino; Antonio Ceriello; Peter Diem; Anne-Marie Felton; Kari Harno; Ilhan Satman; Bruno Vergès
Journal:  J Diabetes Sci Technol       Date:  2014-05-18

5.  Does self monitoring of blood glucose as opposed to urinalysis provide additional benefit in patients newly diagnosed with type 2 diabetes receiving structured education? The DESMOND SMBG randomised controlled trial protocol.

Authors:  Helen M Dallosso; Helen C Eborall; Heather Daly; Lorraine Martin-Stacey; Jane Speight; Kathryn Realf; Marian E Carey; Michael J Campbell; Simon Dixon; Kamlesh Khunti; Melanie J Davies; Simon Heller
Journal:  BMC Fam Pract       Date:  2012-03-14       Impact factor: 2.497

6.  Diabetes mellitus in Zambia and the Western Cape province of South Africa: Prevalence, risk factors, diagnosis and management.

Authors:  Sarah Lou Bailey; Helen Ayles; Nulda Beyers; Peter Godfrey-Faussett; Monde Muyoyeta; Elizabeth du Toit; John S Yudkin; Sian Floyd
Journal:  Diabetes Res Clin Pract       Date:  2016-05-07       Impact factor: 5.602

7.  Supported Telemonitoring and Glycemic Control in People with Type 2 Diabetes: The Telescot Diabetes Pragmatic Multicenter Randomized Controlled Trial.

Authors:  Sarah H Wild; Janet Hanley; Stephanie C Lewis; John A McKnight; Lucy B McCloughan; Paul L Padfield; Richard A Parker; Mary Paterson; Hilary Pinnock; Aziz Sheikh; Brian McKinstry
Journal:  PLoS Med       Date:  2016-07-26       Impact factor: 11.069

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.